請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17445完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳青周(Ching-Chow Chen) | |
| dc.contributor.author | Shao-Pu Tang | en |
| dc.contributor.author | 唐韶璞 | zh_TW |
| dc.date.accessioned | 2021-06-08T00:13:32Z | - |
| dc.date.copyright | 2013-09-24 | |
| dc.date.issued | 2013 | |
| dc.date.submitted | 2013-08-02 | |
| dc.identifier.citation | Albina, J. E., B. Mastrofrancesco, J. A. Vessella, C. A. Louis, W. L. Henry, Jr. and J. S. Reichner (2001). 'HIF-1 expression in healing wounds: HIF-1alpha induction in primary inflammatory cells by TNF-alpha.' Am J Physiol Cell Physiol 281(6): C1971-1977.
Allen-Mersh, T. G., S. Earlam, et al. (1994). 'Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases.' Lancet 344(8932): 1255-1260. Banck, M. S. and A. Grothey (2009). 'Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.' Clin Cancer Res 15(24): 7492-7501. Baranwal, S. and S. K. Alahari (2009). 'Molecular mechanisms controlling E-cadherin expression in breast cancer.' Biochem Biophys Res Commun 384(1): 6-11. Barault, L., C. Charon-Barra, V. Jooste, M. F. de la Vega, L. Martin, P. Roignot, P. Rat, A. M. Bouvier, P. Laurent-Puig, J. Faivre, C. Chapusot and F. Piard (2008). 'Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.' Cancer Res 68(20): 8541-8546. Berra, E., A. Ginouves, et al. (2006). 'The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling.' EMBO Rep 7(1): 41-45. Berven, L. A. and M. F. Crouch (2000). 'Cellular function of p70S6K: a role in regulating cell motility.' Immunol Cell Biol 78(4): 447-451. Billam, M., M. D. Sobolewski, et al. (2010). 'Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.' Breast Cancer Res Treat 120(3): 581-592. Bipat, S., A. S. Glas, et al. (2004). 'Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis.' Radiology 232(3): 773-783. Birgisson, H., L. Pahlman, et al. (2005). 'Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial.' J Clin Oncol 23(34): 8697-8705. Bolden, J. E., M. J. Peart, et al. (2006). 'Anticancer activities of histone deacetylase inhibitors.' Nat Rev Drug Discov 5(9): 769-784. Brahimi-Horn, M. C. and J. Pouyssegur (2007). 'Harnessing the hypoxia-inducible factor in cancer and ischemic disease.' Biochem Pharmacol 73(3): 450-457. Brenner, D. J. and E. J. Hall (2007). 'Computed tomography--an increasing source of radiation exposure.' N Engl J Med 357(22): 2277-2284. Bristow, R. G. and R. P. Hill (2008). 'Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability.' Nat Rev Cancer 8(3): 180-192. Brown, G., A. G. Radcliffe, et al. (2003). 'Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging.' Br J Surg 90(3): 355-364. Brune, B. and J. Zhou (2007). 'Nitric oxide and superoxide: interference with hypoxic signaling.' Cardiovasc Res 75(2): 275-282. Burgers, W. A., F. Fuks, et al. (2002). 'DNA methyltransferases get connected to chromatin.' Trends Genet 18(6): 275-277. Camma, C., M. Giunta, et al. (2000). 'Preoperative radiotherapy for resectable rectal cancer: A meta-analysis.' JAMA 284(8): 1008-1015. Carroll, V. A. and M. Ashcroft (2005). 'Targeting the molecular basis for tumour hypoxia.' Expert Rev Mol Med 7(6): 1-16. Chan, D. A. and A. J. Giaccia (2010). 'PHD2 in tumour angiogenesis.' Br J Cancer 103(1): 1-5. Chang, H. H., C. P. Chiang, et al. (2009). 'Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients.' Oral Oncol 45(7): 610-614. Chen, J. B., T. R. Chern, et al. (2013). 'Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.' J Med Chem 56(9): 3645-3655. Chen, S. and N. Sang (2011). 'Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.' J Biomed Biotechnol 2011: 197946. Cheng, J. C., C. B. Matsen, et al. (2003). 'Inhibition of DNA methylation and reactivation of silenced genes by zebularine.' J Natl Cancer Inst 95(5): 399-409. Cheng, J. C., D. J. Weisenberger, et al. (2004). 'Continuous Zebularine Treatment Effectively Sustains Demethylation in Human Bladder Cancer Cells.' Molecular and Cellular Biology 24(3): 1270-1278. Cheng, J. C., C. B. Yoo, et al. (2004). 'Preferential response of cancer cells to zebularine.' Cancer Cell 6(2): 151-158. Choi, J. H., H. J. Kwon, et al. (2001). 'Expression profile of histone deacetylase 1 in gastric cancer tissues.' Jpn J Cancer Res 92(12): 1300-1304. Chou,C.W. (2010). 'Regulation of the expression of ADAMTS1 and EGFR by HDAC inhibitors. ' NTU Doctoral Dissertation:18. Cunningham, D., W. Atkin, et al. (2010). 'Colorectal cancer.' Lancet 375(9719): 1030-1047. Curtin, K., M. L. Slattery and W. S. Samowitz (2011). 'CpG island methylation in colorectal cancer: past, present and future.' Patholog Res Int 2011: 902674. D'Angelo, G., E. Duplan, et al. (2003). 'Hypoxia up-regulates prolyl hydroxylase activity: a feedback mechanism that limits HIF-1 responses during reoxygenation.' J Biol Chem 278(40): 38183-38187. Dayan, F., N. M. Mazure, et al. (2008). 'A dialogue between the hypoxia-inducible factor and the tumor microenvironment.' Cancer Microenviron 1(1): 53-68. De Bock, K., M. Mazzone, et al. (2011). 'Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?' Nat Rev Clin Oncol 8(7): 393-404. De Robertis, M., E. Massi, et al. (2011). 'The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies.' JCarcinog 10: 9. Dehne, N. and B. Brune (2009). 'HIF-1 in the inflammatory microenvironment.' Exp Cell Res 315(11): 1791-1797. Demidenko, Z. N., A. Rapisarda, et al. (2005). 'Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion.' Oncogene 24(30): 4829-4838. Eaden, J. A., K. R. Abrams, et al. (2001). 'The risk of colorectal cancer in ulcerative colitis: a meta-analysis.' Gut 48(4): 526-535. Eads, C. A., K. D. Danenberg, et al. (1999). 'CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression.' Cancer Res 59(10): 2302-2306. Egger, G., G. Liang, et al. (2004). 'Epigenetics in human disease and prospects for epigenetic therapy.' Nature 429(6990): 457-463. Fang, M. Z., Y. Wang, et al. (2003). 'Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines.' Cancer Res 63(22): 7563-7570. Fath, D. M., X. Kong, et al. (2006). 'Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha.' J Biol Chem 281(19): 13612-13619. Folkman, J. (1990). 'What is the evidence that tumors are angiogenesis dependent?' J Natl Cancer Inst 82(1): 4-6. Fong, G. H. (2008). 'Mechanisms of adaptive angiogenesis to tissue hypoxia.' Angiogenesis 11(2): 121-140. Foxler, D. E., K. S. Bridge, et al. (2012). 'The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity.' Nat Cell Biol 14(2): 201-208. Friend, C., W. Scher, et al. (1971). 'Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide.' Proc Natl Acad Sci U S A 68(2): 378-382. Fritzsche, F. R., W. Weichert, et al. (2008). 'Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.' BMC Cancer 8: 381. Frye, R. A. (2000). 'Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins.' Biochem Biophys Res Commun 273(2): 793-798. Fuks, F. (2005). 'DNA methylation and histone modifications: teaming up to silence genes.' Curr Opin Genet Dev 15(5): 490-495. Fullgrabe, J., E. Kavanagh, et al. (2011). 'Histone onco-modifications.' Oncogene 30(31): 3391-3403. Galm, O., J. G. Herman, et al. (2006). 'The fundamental role of epigenetics in hematopoietic malignancies.' Blood Rev 20(1): 1-13. Gao, L., M. A. Cueto, et al. (2002). 'Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family.' J Biol Chem 277(28): 25748-25755. Gerald, D., E. Berra, Y. M. Frapart, D. A. Chan, A. J. Giaccia, D. Mansuy, J. Pouyssegur, M. Yaniv and F. Mechta-Grigoriou (2004). 'JunD reduces tumor angiogenesis by protecting cells from oxidative stress.' Cell 118(6): 781-794. Goodwin, R. A. and T. R. Asmis (2009). 'Overview of systemic therapy for colorectal cancer.' Clin Colon Rectal Surg 22(4): 251-256. Gorlach, A., I. Diebold, V. B. Schini-Kerth, U. Berchner-Pfannschmidt, U. Roth, R. P. Brandes, T. Kietzmann and R. Busse (2001). 'Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of the p22(phox)-containing NADPH oxidase.' Circ Res 89(1): 47-54. Haberland, M., R. L. Montgomery, et al. (2009). 'The many roles of histone deacetylases in development and physiology: implications for disease and therapy.' Nat Rev Genet 10(1): 32-42. Hawkins, N., M. Norrie, K. Cheong, E. Mokany, S. L. Ku, A. Meagher, T. O'Connor and R. Ward (2002). 'CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability.' Gastroenterology 122(5): 1376-1387. Hollander, A. P., K. P. Corke, A. J. Freemont and C. E. Lewis (2001). 'Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint.' Arthritis Rheum 44(7): 1540-1544. Huang, S. Tavare, A. Murrell and J. D. Brenton (2011). 'Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression.' Gut 60(4): 499-508. Hubbert, C., A. Guardiola, et al. (2002). 'HDAC6 is a microtubule-associated deacetylase.' Nature 417(6887): 455-458. Ibrahim, A. E., M. J. Arends, A. L. Silva, A. H. Wyllie, L. Greger, Y. Ito, S. L. Vowler, T. H. Huang, S. Tavare, A. Murrell and J. D. Brenton (2011). 'Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression.' Gut 60(4): 499-508. Jain, R., P. W. Shaul, et al. (2007). 'Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1.' Am J Respir Cell Mol Biol 37(1): 38-47. Jemal, A., F. Bray, et al. (2011). 'Global cancer statistics.' CA Cancer J Clin 61(2): 69-90. Kaluza, D., J. Kroll, et al. (2011). 'Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin.' EMBO J 30(20): 4142-4156. Kapiteijn, E., C. A. Marijnen, et al. (2001). 'Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.' N Engl J Med 345(9): 638-646. Karagiannis, T. C. and K. Ververis (2012). 'Potential of chromatin modifying compounds for the treatment of Alzheimer's disease.' Pathobiol Aging Age Relat Dis 2. Kasper, L. H., F. Boussouar, et al. (2005). 'Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression.' EMBO J 24(22): 3846-3858. Kato, H., S. Tamamizu-Kato, et al. (2004). 'Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity.' J Biol Chem 279(40): 41966-41974. Knowles, H. J., R. R. Raval, et al. (2003). 'Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells.' Cancer Res 63(8): 1764-1768. Kong, X., Z. Lin, et al. (2006). 'Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha.' Mol Cell Biol 26(6): 2019-2028. Kornberg, R. D. and Y. Lorch (1999). 'Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome.' Cell 98(3): 285-294. Kouzarides, T. (2007). 'Chromatin modifications and their function.' Cell 128(4): 693-705. Kouzminova, N., T. Lu, et al. (2010). 'Molecular basis of colorectal cancer.' N Engl J Med 362(13): 1245-1246; author reply 1246-1247. Kristensen, L. S., H. M. Nielsen, et al. (2009). 'Epigenetics and cancer treatment.' Eur J Pharmacol 625(1-3): 131-142. Krock, B. L., N. Skuli, et al. (2011). 'Hypoxia-induced angiogenesis: good and evil.' Genes Cancer 2(12): 1117-1133. Krusche, C. A., P. Wulfing, et al. (2005). 'Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis.' Breast Cancer Res Treat 90(1): 15-23. Lee, K., J. E. Kang, et al. (2010). 'LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line.' Biochem Pharmacol 80(7): 982-989. Lee, J. Y., Y. Nagano, et al. (2010). 'Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy.' J Cell Biol 189(4): 671-679. Li, F., P. Sonveaux, Z. N. Rabbani, S. Liu, B. Yan, Q. Huang, Z. Vujaskovic, M. W. Dewhirst and C. Y. Li (2007). 'Regulation of HIF-1alpha stability through S-nitrosylation.' Mol Cell 26(1): 63-74. Li, Z., S. Bao, et al. (2009). 'Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.' Cancer Cell 15(6): 501-513. Lieberman, D. A. (2009). 'Clinical practice. Screening for colorectal cancer.' N Engl J Med 361(12): 1179-1187. Lin, S. C., C. W. Chien, et al. (2011). 'Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells.' J Clin Invest 121(5): 1905-1916. Linhart, H. G., H. Lin, Y. Yamada, E. Moran, E. J. Steine, S. Gokhale, G. Lo, E. Cantu, M. Ehrich, T. He, A. Meissner and R. Jaenisch (2007). 'Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing.' Genes Dev 21(23): 3110-3122. Liu, K., Y. F. Wang, et al. (2003). 'Endogenous Assays of DNA Methyltransferases: Evidence for Differential Activities of DNMT1, DNMT2, and DNMT3 in Mammalian Cells In Vivo.' Molecular and Cellular Biology 23(8): 2709-2719. Lothe, R. A., P. Peltomaki, et al. (1993). 'Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history.' Cancer Res 53(24): 5849-5852. Lu, X. and Y. Kang (2010). 'Hypoxia and hypoxia-inducible factors: master regulators of metastasis.' Clin Cancer Res 16(24): 5928-5935. Lu, Y., X. Li, et al. (2010). '1, 9-Pyrazoloanthrones downregulate HIF-1alpha and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy.' PLoS One 5(12): e15823. Luger, K., A. W. Mader, et al. (1997). 'Crystal structure of the nucleosome core particle at 2.8 A resolution.' Nature 389(6648): 251-260. Mazure, N. M., M. C. Brahimi-Horn, et al. (2004). 'HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs.' Biochem Pharmacol 68(6): 971-980. McKinsey, T. A., C. L. Zhang, et al. (2000). 'Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation.' Nature 408(6808): 106-111. McMahon, G. (2000). 'VEGF receptor signaling in tumor angiogenesis.' Oncologist 5 Suppl 1: 3-10. Meyerhardt, J. A. and R. J. Mayer (2005). 'Systemic therapy for colorectal cancer.' N Engl J Med 352(5): 476-487. Lee Mie, Y., S. H. Kim, et al. (2003). 'Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity.' Biochem Biophys Res Commun 300(1): 241-246. Mihaylova, M. M. and R. J. Shaw (2013). 'Metabolic reprogramming by class I and II histone deacetylases.' Trends Endocrinol Metab 24(1): 48-57. Miyake, K., T. Yoshizumi, et al. (2008). 'Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation.' Pancreas 36(3): e1-9. Moreno, D. A., C. A. Scrideli, et al. (2010). 'Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia.' Br J Haematol 150(6): 665-673. Muratani, M. and W. P. Tansey (2003). 'How the ubiquitin-proteasome system controls transcription.' Nat Rev Mol Cell Biol 4(3): 192-201. Neureiter, D., S. Zopf, et al. (2007). 'Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models.' Scand J Gastroenterol 42(1): 103-116. Nightingale, K. P., L. P. O'Neill, et al. (2006). 'Histone modifications: signalling receptors and potential elements of a heritable epigenetic code.' Curr Opin Genet Dev 16(2): 125-136. Nordlinger, B., H. Sorbye, et al. (2008). 'Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.' The Lancet 371(9617): 1007-1016. Nosho, K., K. Shima, N. Irahara, S. Kure, Y. Baba, G. J. Kirkner, L. Chen, S. Gokhale, A. Hazra, D. Spiegelman, E. L. Giovannucci, R. Jaenisch, C. S. Fuchs and S. Ogino (2009). 'DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer.' Clin Cancer Res 15(11): 3663-3671. Oehme, I., H. E. Deubzer, et al. (2009). 'Targeting of HDAC8 and investigational inhibitors in neuroblastoma.' Expert Opin Investig Drugs 18(11): 1605-1617. Oellerich, M., V. W. Armstrong, F. Streit, L. Weber and B. Tonshoff (2004). 'Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.' Clin Biochem 37(6): 424-428. Okano, M., D. W. Bell, et al. (1999). 'DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development.' Cell 99(3): 247-257. Ozdag, H., A. E. Teschendorff, et al. (2006). 'Differential expression of selected histone modifier genes in human solid cancers.' BMC Genomics 7: 90. Peltomaki, P. (2003). 'Role of DNA Mismatch Repair Defects in the Pathogenesis of Human Cancer.' Journal of Clinical Oncology 21(6): 1174-1179. Phillips, D. M. and E. W. Johns (1965). 'A FRACTIONATION OF THE HISTONES OF GROUP F2A FROM CALF THYMUS.' Biochem J 94: 127-130. Pouyssegur, J., F. Dayan, et al. (2006). 'Hypoxia signalling in cancer and approaches to enforce tumour regression.' Nature 441(7092): 437-443. Qian, D. Z., S. K. Kachhap, et al. (2006). 'Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha.' Cancer Res 66(17): 8814-8821. Richard, D. E., E. Berra and J. Pouyssegur (2000). 'Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells.' J Biol Chem 275(35): 26765-26771. Rikimaru, T., A. Taketomi, et al. (2007). 'Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma.' Oncology 72(1-2): 69-74. Ropero, S., M. F. Fraga, et al. (2006). 'A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.' Nat Genet 38(5): 566-569. Sakuma, T., K. Uzawa, et al. (2006). 'Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma.' Int J Oncol 29(1): 117-124. Sargent, D. J., S. Patiyil, et al. (2007). 'End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.' J Clin Oncol 25(29): 4569-4574. Semenza, G. L. (2003). 'Targeting HIF-1 for cancer therapy.' Nat Rev Cancer 3(10): 721-732. Shen, L., M. Toyota, et al. (2007). 'Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer.' Proc Natl Acad Sci U S A 104(47): 18654-18659. Silverman, L. R., D. R. McKenzie, et al. (2006). 'Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.' J Clin Oncol 24(24): 3895-3903. Spiegel, S., S. Milstien, et al. (2012). 'Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.' Oncogene 31(5): 537-551. Stein, A., D. Atanackovic, et al. (2011). 'Current standards and new trends in the primary treatment of colorectal cancer.' European Journal of Cancer 47: S312-S314. Straatman, L. P. and J. G. Coles (2000). 'Pediatric utilization of rapamycin for severe cardiac allograft rejection.' Transplantation 70(3): 541-543. Strahl, B. D. and C. D. Allis (2000). 'The language of covalent histone modifications.' Nature 403(6765): 41-45. Tan, W., W. Zhou, et al. (2013). 'The DNA methyltransferase inhibitor zebularine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo.' Biochem Biophys Res Commun 430(1): 250-255. Taunton, J., C. A. Hassig, et al. (1996). 'A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p.' Science 272(5260): 408-411. Terzic, J., S. Grivennikov, et al. (2010). 'Inflammation and colon cancer.' Gastroenterology 138(6): 2101-2114 e2105. Thiery, J. P. and J. P. Sleeman (2006). 'Complex networks orchestrate epithelial-mesenchymal transitions.' Nat Rev Mol Cell Biol 7(2): 131-142. Toyota, M., N. Ahuja, et al. (1999). 'CpG island methylator phenotype in colorectal cancer.' Proc Natl Acad Sci U S A 96(15): 8681-8686. Van Rijnsoever, M., F. Grieu, H. Elsaleh, D. Joseph and B. Iacopetta (2002). 'Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands.' Gut 51(6): 797-802. Vaupel, P., S. Briest, et al. (2002). 'Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications.' Wien Med Wochenschr 152(13-14): 334-342. Vega, R. B., B. C. Harrison, et al. (2004). 'Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5.' Mol Cell Biol 24(19): 8374-8385. Venugopal, B. and T. R. Evans (2011). 'Developing histone deacetylase inhibitors as anti-cancer therapeutics.' Curr Med Chem 18(11): 1658-1671. Vogelstein, B., E. R. Fearon, et al. (1988). 'Genetic alterations during colorectal-tumor development.' N Engl J Med 319(9): 525-532. Waldner, M. J. and M. F. Neurath (2010). 'The molecular therapy of colorectal cancer.' Mol Aspects Med 31(2): 171-178. Walther, A., E. Johnstone, et al. (2009). 'Genetic prognostic and predictive markers in colorectal cancer.' Nat Rev Cancer 9(7): 489-499. Wang, Y. and M. Ohh (2010). 'Oxygen-mediated endocytosis in cancer.' J Cell Mol Med 14(3): 496-503. Weichert, W., A. Roske, et al. (2008). 'Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.' Br J Cancer 98(3): 604-610. Weisenberger, D. J., K. D. Siegmund, et al. (2006). 'CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.' Nat Genet 38(7): 787-793. Wenger, R. H. (2002). 'Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression.' FASEB J 16(10): 1151-1162. Wenger, R. H., D. P. Stiehl, et al. (2005). 'Integration of oxygen signaling at the consensus HRE.' Sci STKE 2005(306): re12. Wilson, W. R. and M. P. Hay (2011). 'Targeting hypoxia in cancer therapy.' Nat Rev Cancer 11(6): 393-410. Yang, P. M., Y. L. Liu, et al. (2010). 'Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies.' Cancer Res 70(19): 7699-7709. Yang, Q. C., B. F. Zeng, et al. (2006). 'Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma.' J Exp Clin Cancer Res 25(4): 593-599. Yoo, C. B., J. C. Cheng, et al. (2004). 'Zebularine: a new drug for epigenetic therapy.' Biochem Soc Trans 32(Pt 6): 910-912. Yotnda, P., D. Wu, et al. (2010). 'Hypoxic tumors and their effect on immune cells and cancer therapy.' Methods Mol Biol 651: 1-29. You, B. R. and W. H. Park (2012). 'Zebularine inhibits the growth of HeLa cervical cancer cells via cell cycle arrest and caspase-dependent apoptosis.' Mol Biol Rep 39(10): 9723-9731. Zgouras, D., A. Wachtershauser, et al. (2003). 'Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1α nuclear translocation.' Biochemical and Biophysical Research Communications 300(4): 832-838. Zhang, Z., H. Yamashita, et al. (2005). 'Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast.' Breast Cancer Res Treat 94(1): 11-16. Zhong, H., A. M. De Marzo, E. Laughner, M. Lim, D. A. Hilton, D. Zagzag, P. Buechler, W. B. Isaacs, G. L. Semenza and J. W. Simons (1999). 'Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.' Cancer Res 59(22): 5830-5835. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17445 | - |
| dc.description.abstract | 中文摘要
缺氧誘導因子HIF-1α在腫瘤生長及產生血管新生因子VEGF而導致血管新生扮演重要角色，HIF-1α遂成為抗癌新標靶，我們開發的新穎抗癌小分子藥物JMF compounds，可同時抑制HDAC及HMG Co-A還原酶的活性，而WJ compound則為一新穎之 pan-HDAC抑制劑，JMF及WJ在大腸直腸癌細胞可透過抑制P-AKT pathway抑制HIF-1α之表現，並以Matrigel plug證明JMF可抑制血管新生，口服給予JMF在azoxymethane (AOM)/dextran sulphate sodium (DSS)誘導之小鼠大腸直腸癌動物模式中，可抑制HIF-1α、VEGF及改善缺氧微環境，故JMF及WJ極具潛力成為預防癌症或抗癌之新藥物。 Zebularine為DNA methyltransferase (DNMT) inhibitor，對正常細胞低毒性，我們發現Zebularine在大腸直腸癌細胞可透過Hydroxylation使HIF-1α不穩定而分解，並以Matrigel plug證明Zebularine可抑制血管新生，且能提升大腸直腸癌細胞對化療藥之感受性，亦在大腸直腸癌細胞Xenograft 動物模式提升HIF-1α之Hydroxylation並抑制HIF-1α及其下游之VEGF，Zebularine亦提升Oxaliplatin在azoxymethane (AOM)/dextran sulphate sodium (DSS)誘導小鼠大腸直腸癌動物模式中之治療效果，這些結果指出，Zebularine極具潛力成為抗癌藥之輔助藥物。 | zh_TW |
| dc.description.provenance | Made available in DSpace on 2021-06-08T00:13:32Z (GMT). No. of bitstreams: 1 ntu-102-R00443010-1.pdf: 47125638 bytes, checksum: 293bf4cf898fd202ee64df22d2451056 (MD5) Previous issue date: 2013 | en |
| dc.description.tableofcontents | 目錄
縮寫表………………………………………………………….…………2 中文摘要…………………………………………………………….……5 Abstract…………………………………………………………….……...6 第一章 緒論……………………………………………………….……..9 第一節 Colorectal cancer (CRC)…………………………….……..9 第二節 Hypoxia……………………………………………….…..17 第三節 Histone deacetylase inhibitor (HDACi)…………….…….31 第四節 DNMT Inhibitor-Zebularine………………………….…..39 第五節 研究動機…………………………………………….……44 第二章 實驗材料與方法………………………………………….……46 第三章 結果………………………………………………….…………54 第四章 討論……………………………………………………….……77 第五章 結論…………………………………………………….………83 參考文獻……………………………………………………….………..86 | |
| dc.language.iso | zh-TW | |
| dc.title | Epigenetic藥物抑制HIF-1α之研究 | zh_TW |
| dc.title | Investigation of HIF-1α Regulation by Epigenetic drugs | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 101-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 吳明賢,黃偉謙 | |
| dc.subject.keyword | 缺氧誘導因子,血管新生因子, | zh_TW |
| dc.subject.keyword | HIF-1α,VEGF, | en |
| dc.relation.page | 95 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2013-08-02 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥理學研究所 | zh_TW |
| 顯示於系所單位： | 藥理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-102-1.pdf 未授權公開取用 | 46.02 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。